Nurix and Seagen Collaborate on Breakthrough Cancer Therapeutics

Nurix and Seagen to develop a portfolio of Degrader-Antibody Conjugates (DACs): antibodies that deliver a targeted protein degrader payload to selectively kill cancer cells

Nurix to receive a $60 million upfront payment, in addition to the potential for approximately $3.4 billion in milestone payments plus future royalties

Nurix retains an option for U.S. profit sharing and co-promotion on two products arising from the collaboration